Mikhail Blagosklonny Finds Longevity Properties In Rapamycin

Mikhail Blagosklonny is a professor, philanthropist and researcher whose goal is to ensure that all individuals around the world receive the best medical treatment regardless of their economic situation. Mikhail Blagosklonny has focused in the field of medical research that is studying aging and cancer. Mikhail Blagosklonny believes that there is a connection between the two as cancer is more common among older individuals. Many professionals and students in the oncology field have been inspired by Mikhail Blagosklonny’s work on the subject.

Mikhail Blagosklonny’s career has been about researching techniques that reduce the cost and pain of treating cancer. He has made great progress in developing ways of removing cancerous cells without destroying normal, healthy cells that are vital in recovering the body after months of cancer treatment. Mikhail Blagosklonny’s research, which is published on impactjournals.com, has generated a lot of attention in the medical field.

Mikhail Blagosklonny spends most of his days working as a professor of oncology at the Roswell Park Cancer Institute in New York. Additionally, he serves as the editor in chief of Oncotarget, a peer reviewed journal that offers open access to medical research on oncology, aging, immunology, pathology, autophagy and other fields of medical research.

At Roswell Park Cancer Institute, Mikhail Blagosklonny has been advocating the use of Rapamycin as an anti-aging treatment. Rapamycin is a drug that was first isolated in 1972 from a bacterium found in Sirolimus. Initially the drug was used an anti-fungal agent before researchers discovered the anti-proliferative and immunosuppressive properties of the drug. In the 21st Century the drug is used to prevent organ transplant rejection, as a coating for coronary stents and for treating rare lung diseases. The drug is marketed under the trade name, Rapamune.

Mikhail Blagosklonny has been conducting research in the use of Rapamycin as an anti-aging therapy. He has conducted research that proved Rapamycin treatment enhanced the ability of old mice to combat tuberculosis infections. Additionally, initial studies on humans have shown increase immunological rejuvenation on old patients who received a dose of Rapamycin prior to receiving an influenza vaccination. However, no conclusive evidence has been found that shows Rapamycin increases longevity in human beings. Mikhail Blagosklonny is a believer that Rapamycin can help slow down the aging process. Scientists led by Mikhail Blagosklonny have been studying the effects of Rapamycin on marmoset monkeys.

Rapamycin has also shown promise in treating other diseases. Studies using Rapamycin have shown that Rapamycin helps heal brain lesions and improving cognitive abilities in mice affected by Alzheimer’s. This research is promising as Alzheimer’s is a disease that has no cure and is expensive to manage. After organ transplants, the human body usually rejects the transplanted organ. This leads doctors to prescribe immunosuppressants that prevent the body’s immune system from attacking the transplanted organ. However, most immunosuppressants have an adverse impact on the kidney after long use. Rapamycin has been used as an immunosuppressant due to its low level of toxicity towards kidneys.